PAG
VRTX icon

Private Advisor Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Private Advisor Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500
Closed -$1.74K – 2527
2023
Q3 		$1.74K Buy
+500
New +$175K ﹤0.01% 2238

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Private Advisor Group's VRTX Position: Q2 2026 in Review

Private Advisor Group reduced its Vertex Pharmaceuticals (VRTX) stake by 51% in Q2 2026, selling an estimated $1.91M and leaving 4,130 shares worth $2.05M. The position accounts for 0.01% of the portfolio, ranked #1006.

Private Advisor Group first reported a position in VRTX in Q4 2014 and has held it in 47 quarters since. The position peaked at $8.95M in Q2 2022. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Private Advisor Group held 4,130 shares of Vertex Pharmaceuticals worth $2.05M as of Q2 2026.
  • Private Advisor Group sold 4,303 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.91M.
  • Vertex Pharmaceuticals made up 0.01% of Private Advisor Group's portfolio in Q2 2026, its #1006 holding.
  • Private Advisor Group first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • Private Advisor Group's Vertex Pharmaceuticals position peaked at $8.95M in Q2 2022.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.